
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. demonstrates a strong growth trajectory, evidenced by 3Q sales of $31.6 million, which reflects an increase from the previous quarter, alongside a notable rise in total prescriptions (TRx) to 53,000. The company is expected to achieve cash flow-positive status by 2026, driven by projected revenue growth outpacing operational costs and improving operating margins. Additionally, the increasing market penetration of its lead product, AXS-05, following positive Phase III data and expanding coverage, positions the company favorably for future success in managing central nervous system disorders.
Bears say
The financial outlook for Axsome Therapeutics is negatively impacted by several key risks associated with its product pipeline and market performance. Significant concerns include the potential for lower-than-expected market access for AUVELITY and setbacks in clinical trials for AXS-05 and other candidates, which could hinder the company's growth prospects. Additionally, factors such as competitive pressures and the risk of dilution may further strain the company's ability to achieve projected commercial success and secure necessary approvals.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares